Search
Odronextamab
go.drugbank.com/drugs/DB16684ApprovedInvestigational[A254187] In December 2020, the FDA placed a partial clinical hold and requested the drug developer, Regeneron Pharmaceuticals, to amend clinical protocols to reduce the incidence of CRS. … [A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can lead to the development
Mitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigational[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. … [A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigational[A243759] The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in the destruction of these receptors … [A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG.
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. … [L43747] On December 12, 2025, the FDA expanded niraparib and abiraterone acetate (AKEEGA) with prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer
Flunitrazepam
go.drugbank.com/drugs/DB01544ApprovedIllicitThe United States Government has banned the importation of this drug. … Flunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia.
Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251365] The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.[A251165] … [A251370] While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation.
Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnDue to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalmultiple organs, although wild-type misfolded TTR has also been observed to contribute to the disease pathophysiology. … [A262990] On December 21, 2023, the FDA approved eplontersen under the brand name WAINUA for the treatment of adult polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body. … voltage-gated sodium channels, thus preventing their return to the activated state during which seizure activity can occur.
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.
International brands: Ea Ten